Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
bladder cancer
enfortumab vedotin
metastasis
urothelial cancer
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
12
2020
accepted:
30
01
2021
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
7
10
2021
Statut:
epublish
Résumé
Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.
Identifiants
pubmed: 33603337
doi: 10.2147/DDDT.S240854
pii: 240854
pmc: PMC7886109
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
enfortumab vedotin
DLE8519RWM
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-462Informations de copyright
© 2021 Moussa et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Ann Pharmacother. 2020 Sep 18;:1060028020960402
pubmed: 32945172
Pharmaceuticals (Basel). 2020 Mar 05;13(3):
pubmed: 32151051
Am Soc Clin Oncol Educ Book. 2019 Jan;39:284-300
pubmed: 31099684
Invest New Drugs. 2020 Aug;38(4):1056-1066
pubmed: 31444589
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S105-15
pubmed: 12850531
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Anticancer Drugs. 2016 Jan;27(1):48-53
pubmed: 26421462
Cureus. 2020 May 13;12(5):e8102
pubmed: 32542157
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
J Dermatol. 2020 Dec;47(12):1436-1438
pubmed: 32860247
Ther Clin Risk Manag. 2018 Jun 05;14:1019-1040
pubmed: 29892196
Annu Rev Cell Dev Biol. 2008;24:309-42
pubmed: 18593353
Expert Opin Biol Ther. 2020 Dec 27;:1-9
pubmed: 33325754
Eur J Cancer. 2006 Jan;42(1):50-4
pubmed: 16330205
Eur Urol. 2020 Dec;78(6):893-906
pubmed: 32972792
Cancer Manag Res. 2020 Sep 11;12:8379-8386
pubmed: 32982431
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-17
pubmed: 32315240
Cancer Treat Rev. 2019 Jun;76:10-21
pubmed: 31030123
Expert Opin Investig Drugs. 2019 Oct;28(10):821-826
pubmed: 31526130
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140